Most Read

The global partnership, which will exclude the Greater China region, is expected to fetch more than $350m to Kelun-Biotech in addition to royalties based on annual net sales.

The randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the U.S., Canada, Israel, and Turkey, and enroll approximately 260 patients. The Company

In their study in mice, the scientists discovered that liver injury triggered senescence, which is normally associated with aging or chronic disease. The researchers found that certain anti-cancer

Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica’s cloud-based proteome Ligand Express screening platform to investigate the off-target profiles of small molecules, apply Cyclica’s novel and

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to

Under the deal, the partnership will carry out research and development activities for the advancement of mRNA-based flu vaccines. BioNTech co-founder and CEO Dr Ugur Sahin said: “Today’s

Based in Vienna, Austria, Haplogen is a biotechnology company focused on developing therapeutic substances for the treatment and prevention of infection by the common cold virus. The multi-year

Ankylosing spondylitis is a painful and progressive type of arthritis, in which some or all of the joints and bones of the spine fuse together. The disease is

With this decision, eligible adults in the UK with hATTR amyloidosis can gain access to patisiran before the drug is granted marketing authorization by the European Commission (EC).